Cytek Biosciences Quarterly Balance Sheet
NASDAQ: CTKBIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cytek Biosciences financial position
As of Jun 30, 2026, Cytek Biosciences reported total assets of $446.9 million, down 9.4% from a year earlier against total liabilities of $125.0 million. Shareholders' equity stood at $322.0 million, or 72.0% of assets. The company held $73.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.48, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Cytek Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 73.85M | 65.67M | 90.85M | 93.28M | 75.47M | 95.30M | 98.72M | 162.27M | 177.89M | 168.79M | 167.30M | 163.63M |
| Receivables | 49.70M | 51.90M | 62.51M | 56.63M | 56.23M | 55.03M | 60.59M | 52.63M | 44.64M | 50.31M | 55.93M | 55.40M |
| Inventory | 52.25M | 49.79M | 48.43M | 51.65M | 49.49M | 45.35M | 43.89M | 46.80M | 50.07M | 54.74M | 60.88M | 66.88M |
| Total Current Assets | 377.93M | 379.30M | 392.00M | 388.49M | 382.82M | 380.50M | 396.45M | 390.19M | 384.08M | 388.65M | 392.06M | 422.31M |
| Property, Plant & Equipment | 20.80M | 20.47M | 18.01M | 18.05M | 18.35M | 17.83M | 17.96M | 18.51M | 18.11M | 18.25M | 18.41M | 17.41M |
| Goodwill | 16.69M | 16.69M | 16.70M | 16.70M | 16.71M | 16.68M | 16.66M | 16.18M | 16.18M | 16.18M | 16.18M | 16.46M |
| Intangible Assets | 14.87M | 15.70M | 16.82M | 17.68M | 18.60M | 19.43M | 20.13M | 20.49M | 21.42M | 22.25M | 23.08M | 24.29M |
| Total Assets | 446.93M | 449.11M | 461.54M | 494.92M | 493.32M | 482.60M | 499.50M | 491.23M | 483.73M | 492.07M | 494.46M | 519.43M |
| Accounts Payable | 8.41M | 6.74M | 6.41M | 7.63M | 6.85M | 6.25M | 5.53M | 5.39M | 3.19M | 3.73M | 3.03M | 4.71M |
| Total Current Liabilities | 84.33M | 80.94M | 77.80M | 75.21M | 73.27M | 67.69M | 67.66M | 62.80M | 52.38M | 55.57M | 56.23M | 58.69M |
| Total Liabilities | 124.98M | 121.47M | 119.80M | 116.35M | 115.76M | 102.97M | 103.76M | 105.76M | 94.60M | 99.45M | 101.39M | 103.91M |
| Shareholders' Equity | 321.95M | 327.64M | 341.74M | 378.57M | 377.56M | 379.62M | 395.74M | 385.46M | 389.12M | 392.61M | 393.06M | 415.52M |
| Retained Earnings | -132.76M | -120.60M | -101.74M | -57.66M | -52.18M | -46.60M | -35.20M | -44.84M | -45.78M | -35.35M | -29.18M | -34.68M |
| Net Cash (Debt) | 73.85M | 65.67M | 90.85M | 93.28M | 75.47M | 95.30M | 98.72M | 162.27M | 177.89M | 168.79M | 167.30M | 163.63M |
| Shares Outstanding | 129.98M | 129.14M | 128.55M | 127.86M | 127.19M | 127.60M | 129.21M | 129.77M | 131.51M | 131.25M | 130.71M | 135.55M |
This table shows 12 quarterly periods of Cytek Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 15 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow CTKB's reporting calendar. What is a balance sheet?